BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 14.91% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$8.3 million (up 5.6% YoY), and the FY2025 full-year result was -$8.0 million, down 5.56% from the prior year.
• Income from Non-Controlling Interests retreated to -$2.5 million in Q1 2026, from -$1.8 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $7.3 million in Q2 2022 to a low of -$4.9 million in Q1 2022.
• A 5-year average of -$1.9 million and a median of -$2.2 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests soared 227.44% in 2022 and plunged 138.43% in 2023, its largest moves.
• Tracing BBIO's Income from Non-Controlling Interests over 5 years: stood at -$3.0 million in 2022, then climbed by 26.82% to -$2.2 million in 2023, then dropped by 7.29% to -$2.3 million in 2024, then rose by 24.24% to -$1.8 million in 2025, then slumped by 41.76% to -$2.5 million in 2026.
• Business Quant data shows BBIO's Income from Non-Controlling Interests at -$2.5 million in Q1 2026, -$1.8 million in Q4 2025, and -$2.2 million in Q3 2025.